This is a great article Id like to share
Sydney Morning Herald, the Age Melbourne
Any review of Victoria’s mental health services must look beyond psychiatry.
John Read
September 15, 2011
Opinion
SERIOUS problems in Victoria’s mental health system have been revealed recently in The Age. The important thing now is to find solutions. In doing so we should remember that although Victoria is in the spotlight, similar ”crises” occur regularly all over the world. Perhaps this is because Victoria is not alone in having a system based on fundamentally flawed principles.
Mental health services have become increasingly dominated by psychiatry’s ”medical model”, which claims that feeling depressed, anxious or paranoid is primarily caused by genetic predispositions and chemical imbalances.
This has led to alarming rises in chemical solutions to distress. In New Zealand, one in nine adults (and one in five women) is prescribed antidepressants every year.
The public, however, in every country studied, including Australia, believes that mental health problems are caused by issues such as stress, poverty and isolation. The public also prefers talking therapies to drugs and electroconvulsive therapy (ECT).
Research suggests the public is right. For example, the single best predictor of just about every mental health problem is poverty, followed by other social factors such as abuse, neglect and early loss of parents in childhood, and – once in adulthood – loneliness and a range of adverse events including losses and defeats of various kinds.
Meanwhile, reviews of studies on anti-depressants (which only recently have been able to include those previously kept secret by drug companies) conclude that they are superior to placebos only for those at the extreme end of the ”most severe” group of depressed people. This represents less than 10 per cent of the people who are receiving these drugs.
A recent Cochrane review (the type most highly regarded in the scientific community) for risperidone, a leading anti-psychotic drug, ”suggests that there is no clear difference between risperidone and [a] placebo”.
A placebo (from the Latin meaning ”I please”) is not necessarily a bad thing. Indeed the talking therapies are effective partly because, if done well, they too instil hope and expectations of recovery.
The problem is that psychiatric drugs often have serious adverse effects. Anti-psychotics, for instance, can cause rapid weight gain, loss of sexual function, diabetes, heart disease, neurodegeneration and reduced life span.
As previously reported, my review of ECT studies (with Professor Richard Bentall of Liverpool University) found that this treatment is ineffective for most recipients and frequently causes permanent memory loss. This in itself can be depressing.
ECT also has a slight but significant risk of death, most frequently from cardiovascular failure.
Inpatient units are equally ineffective and can also be damaging. When will we learn that putting large numbers of extremely distressed people in the same building is not a good idea?
What I conclude from all this is that any review of mental health services in Victoria, or anywhere else for that matter, should probably be led by anyone other than a psychiatrist – and certainly not in Victoria’s case the state’s Chief Psychiatrist, whose job, according to Dr Ruth Vine herself, is “to watch over how the system is functioning”.
It is unfair to expect Dr Vine to take an objective view on the failure of the system for which she is responsible. That lack of objectivity is amply demonstrated by her claims that ECT is “safe and effective” and that the problem is the public’s “negative” views. Perhaps a lawyer from the Mental Health Legal Centre might be a good choice.
Any review should include mental health service users and their families, and other mental health professionals, including social workers, occupational therapists, psychologists and nurses.
(Psychiatric nurse Philip Lynch reminds us that there are thousands of staff “who quietly continue to do important work every day, often in challenging circumstances”; so why only listen to the doctors?)
The review should also investigate what percentage of people receive drugs, and what percentage receive safer, more effective alternatives, and how a better balance can be achieved. It must scrutinise the contact and transactions between psychiatrists and drug company reps and consider ways to reduce or eliminate these, and as well find ways to reduce the pressure on psychiatrists by helping them feel OK about sharing decision-making. When things go wrong, as they inevitably will sometimes, everyone should share responsibility, and support one another.
The review would need to explore the ”recovery model” recently introduced in many other countries, including New Zealand. (No, I am not saying New Zealand is superior to Australia – except, of course, when it comes to rugby.)
Further, the review would need to learn from the many innovative non-government organisations, such as Voices Vic and Mind, and study ways to prevent mental health problems developing – perhaps by focusing on providing safe and nurturing environments in the first few years of life. Also, simply listen to the public.
Finally, The Age can assist by reporting the issues without exaggerated headlines such as “1000 DEATHS”.
Dr John Read is a professor of clinical psychology at Auckland University. He advises that no one should reduce or come off medication on the basis of information in this article but should, if they have concerns, consult the prescribing doctor.
http://www.smh.com.au/opinion/society-and-culture/with-more-talk-in-mind-20110914-1k9m2.html
November 17, 2011 at 1:56 am
the following comment is part of a response to this article that i wrote a couple of months back…
I’ve been mulling over John Read’s article, posted in advance of our clinical lectures, which was published in The Sydney Morning Herald this month.
I agree, in the main, and admire any effort to effect a conversation about mental health services and the safety and efficacy of treatments. That said, any such conversation needs show careful application of information, and awareness of its inferential potency when in possession of a sometimes infinitely credulous public.
This article seems a somewhat hyperbolic account of conventional psychiatric treatments, and one that, I fear, may spook people from approaching the related services for intervention.
I ought disclaim here, that I am somebody who has been, and is presently, treated within the psychiatric services of the public health system. I have resisted, but now subscribe to, treatment that has involved inpatient care, medications, supported living, and psychosocial rehabilitation. Disclaimer offered, I envisage that most reading the article lug some back-story, prenotion or mind-baggage into play.
My worry is that a ‘straw-man’ of psychiatry is presented here. Psychiatry is more and more approaching treatment using an interdisciplinary treatment model, rather than a one that’s solely medical. Genetic precursors, life events, chemical happenings, environmental stresses and such are treated as enmeshed. A medical model and a ‘recovery’ model need not be mutually exclusive.
Read’s suggestion that ‘inpatient units are equally ineffective and can also be damaging’ seems a simplistic take on things. When one is at risk of harming others or oneself, such places can provide a respite of sorts. Sure, it’s not optimal. Sometimes it’s pretty darned horrific. And they sure need work. But it beats the option of romping the streets, lying in filth and terror within one’s own home or relying on self-incapacitation by way of drugs and booze … those situations can be at least, if not much more, unsafe.
Also, the information extracted from the Cochrane report with regards to risperidone demands a little more context. The particular study rendered some pretty murky conclusions (nothing hardboiled) but did state:
‘Risperidone appears to have a marginal benefit in terms of clinical improvement compared with placebo in the first few weeks of treatment ‘
and …
‘This review supports the notion that risperidone is more effective than placebo for people with schizophrenia in terms of marginal improvements in symptoms, and in terms of adhering to the medication for longer’.
So the Sydney Herald article’s statement that ‘a recent Cochrane review (the type most highly regarded in the scientific community) for risperidone, a leading anti-psychotic drug, ”suggests that there is no clear difference between risperidone and [a] placebo”’ seems to be hauled in at at the expense of its context.
Where Read suggests ‘the review should also investigate what percentage of people receive drugs, and what percentage receive safer, more effective alternatives’, I think again, facts are being compromised, perhaps merely for the sake of brevity.
I am assuming that these ‘safer, more effective alternatives’ are psychological, psychosocial or psychotherapeutic in kind (I may be wrong, here).
There is nothing, offered here at least, to substantiate the claim that these alternatives are indeed ‘safer’ or ‘more effective’. Maybe when individuals are wellish, maybe as an adjunct to medication, maybe as a standalone treatment for those individuals who can get through sans medication… I don’t know.
I would be interested in any thoughts. And I thank John Read’s article for making me think.